TANDEM DIABETES CARE INC
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.0B | $940.2M | $747.7M | $801.2M | $702.8M |
| Gross profit | $546.0M | $489.6M | $367.7M | $413.0M | $376.2M |
| Operating income | -$187.3M | -$99.1M | -$233.2M | -$92.8M | $22.7M |
| Operating expenses | $733.3M | $588.7M | $600.9M | $505.8M | $353.6M |
| Cost of revenue | $468.7M | $450.6M | $380.0M | $388.2M | $326.6M |
| Cash from operations | -$9.7M | $24.2M | -$31.8M | $50.5M | $111.4M |
| Capital expenditure | $19.9M | $19.2M | $26.8M | $34.1M | $14.2M |
| Free cash flow | -$29.7M | $5.0M | -$58.6M | $16.4M | $97.2M |
| Share repurchases | $0 | $30.0M | $0 | $0 | — |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $881.1M | $967.7M | $952.7M | $1.1B | $905.1M |
| Total liabilities | $725.9M | $704.6M | $639.0M | $612.8M | $472.0M |
Shares outstanding 68.5M · Free float 96.1%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.